Clinical Report: Associations Between Early High-Resolution Immune Profiles and Outcomes in Allogeneic Hematopoietic Cell Transplant Recipients

Overview

This study evaluates the immune cell composition and function in 77 adult allo-HCT recipients at day +28 post-transplantation. Findings indicate that improved survival correlates with increased immune cell counts and elevated cytokine responses, while certain immune markers are associated with poorer outcomes.

Background

Allogeneic hematopoietic cell transplantation (allo-HCT) is a critical treatment for various hematological malignancies, yet complications such as relapse and graft-versus-host disease (GvHD) pose significant risks. Understanding the immune status post-transplant is essential for monitoring and improving patient outcomes. This study aims to identify early prognostic biomarkers through high-resolution immunophenotyping and functional immune profiling.

Data Highlights

Key Findings

• Improved survival is associated with increased counts of both innate and adaptive immune cells.
• Elevated cytokine release following immune stimulation correlates with better survival outcomes.
• Higher levels of myeloid and innate lymphoid subsets are linked to a lower incidence of relapse.
• Increased PD-1 expression on CD4 T cells is associated with poorer overall survival.
• HLA-DR expression on CD8 T cells correlates with worse overall survival outcomes.

Clinical Implications

The findings suggest that early immune profiling could serve as a valuable tool for monitoring allo-HCT patients. Identifying specific immune markers may help in tailoring immunomodulation strategies and improving patient management.

Conclusion

This study highlights the significance of early immune reconstitution in allo-HCT outcomes, suggesting that comprehensive immune profiling may enhance patient monitoring and inform therapeutic strategies.

Related Resources & Content

1. Bone Marrow Transplantation, 2015 -- Elevated Levels of Regulatory T Cells in PBSC Grafts Correlate with Enhanced Survival Following Allogeneic Hematopoietic Stem Cell Transplantation
2. Bone Marrow Transplantation, 2021 -- Association of Antigen-Specific T Cell Responses with Reduced Incidence of Acute Graft-Versus-Host Disease in a Contemporary Multicenter Cohort
3. Bone Marrow Transplantation, 2023 -- Influence of Donor Age and Relationship on the Outcomes of Peripheral Blood Haploidentical Hematopoietic Cell Transplantation
4. Bone Marrow Transplantation, 2024 -- Comparative Analysis of Immune Recovery and Infection Rates Following Allogeneic Hematopoietic Cell Transplantation: The Impact of Post-Transplantation Cyclophosphamide, ATLG, and Non-ATLG GvHD Prophylaxis
5. ScienceDirect, 2025 -- Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group
6. New England Journal of Medicine, 2022 -- Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
7. Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group
8. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis | New England Journal of Medicine